Application of Transcranial Magnetic Stimulation Technology in the Management of Motor Symptoms of Parkinson’s Disease

Objective: To study the effect of transcranial magnetic stimulation (TMS) on improving motor symptoms in patients with Parkinson’s disease (PD). Methods: 60 PD patients who visited the hospital from September 2023 to August 2024 were selected as samples and randomly divided into two groups. Group A received conventional medication plus TMS treatment, while Group B received medication only. The efficacy of motor function improvement, neurological symptoms, mental state, sleep quality, quality of life, and adverse reactions was compared between the two groups. Results: The efficacy of Group A was higher than that of Group B (P < 0.05). The scores of the Scales for Outcomes in Parkinson’s Disease-Autonomic (SCOPA-AUT), Mini-Mental State Examination (MMSE), and Pittsburgh Sleep Quality Index (PSQI) in Group A were lower than those in Group B (P < 0.05). The quality of life scale (SF-36) score in Group A was higher than that in Group B (P < 0.05). The adverse reaction rate in Group A was lower than that in Group B (P < 0.05). Conclusion: TMS used in the treatment of PD patients can improve patients’ mental state and motor function, optimize sleep quality and quality of life, and is safe and efficient.